Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9363061 | 0.82 | CA12 (0.46) | CA12CA1CA9PREPESR1 | |
| SCHEMBL2090369 | 0.81 | CA12 (0.49) | CA12CA1CA9PREP | |
| SCHEMBL30490014 | 0.81 | ALDH1A1 (0.53) | CA12CA1CA9ALOX15 | |
| SCHEMBL2132239 | 0.81 | CA12 (0.45) | CA12CA1CA9THRBPREP | |
| SCHEMBL9013589 | 0.80 | CA12 (0.47) | CA12CA1CA9PREP | |
| SCHEMBL6765739 | 0.80 | CA12 (0.47) | CA12CA1CA9ALOX12PREP | |
| SCHEMBL16135178 | 0.79 | TUBB4A (0.49) | CA12CA1CA9ALOX15ALOX12 | |
| SCHEMBL14992681 | 0.79 | CA12 (0.46) | CA12CA1CA9THRATHRB | |
| SCHEMBL15124366 | 0.79 | CA1 (0.46) | CA12CA1CA9PREP | |
| SCHEMBL12492971 | 0.79 | CA12 (0.46) | CA12CA1CA9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| EP-1748993-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | PPARG, PPARA, PPARD | CA12 4869/4885CA1 4882/4885CA9 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.